|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SF3B14 |
Gene summary for SF3B14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SF3B14 | Gene ID | 51639 |
| Gene name | splicing factor 3b subunit 6 | |
| Gene Alias | CGI-110 | |
| Cytomap | 2p23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q9Y3B4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51639 | SF3B14 | Pt13.a | Human | Liver | HCC | 3.02e-51 | 8.00e-01 | 0.021 |
| 51639 | SF3B14 | Pt13.b | Human | Liver | HCC | 1.36e-82 | 9.67e-01 | 0.0251 |
| 51639 | SF3B14 | Pt13.c | Human | Liver | HCC | 8.42e-06 | 3.48e-01 | 0.0076 |
| 51639 | SF3B14 | Pt14.a | Human | Liver | HCC | 1.47e-28 | 8.94e-01 | 0.0169 |
| 51639 | SF3B14 | Pt14.b | Human | Liver | HCC | 5.32e-40 | 1.02e+00 | 0.018 |
| 51639 | SF3B14 | Pt14.d | Human | Liver | HCC | 6.07e-44 | 7.52e-01 | 0.0143 |
| 51639 | SF3B14 | P1_S1_AK | Human | Skin | AK | 6.46e-20 | -4.65e-01 | -0.3399 |
| 51639 | SF3B14 | P2_S3_AK | Human | Skin | AK | 1.20e-20 | -4.65e-01 | -0.3287 |
| 51639 | SF3B14 | P2_S4_SCCIS | Human | Skin | SCCIS | 2.79e-20 | -4.65e-01 | -0.3043 |
| 51639 | SF3B14 | P3_S6_AK | Human | Skin | AK | 5.14e-21 | -4.65e-01 | -0.3256 |
| 51639 | SF3B14 | P4_S8_cSCC | Human | Skin | cSCC | 9.55e-11 | -4.65e-01 | -0.3095 |
| 51639 | SF3B14 | P5_S10_cSCC | Human | Skin | cSCC | 5.14e-21 | -4.65e-01 | -0.299 |
| 51639 | SF3B14 | P1_cSCC | Human | Skin | cSCC | 1.50e-60 | 2.12e+00 | 0.0292 |
| 51639 | SF3B14 | P2_cSCC | Human | Skin | cSCC | 3.82e-65 | 1.55e+00 | -0.024 |
| 51639 | SF3B14 | P4_cSCC | Human | Skin | cSCC | 1.64e-71 | 1.78e+00 | -0.00290000000000005 |
| 51639 | SF3B14 | P10_cSCC | Human | Skin | cSCC | 3.40e-67 | 2.08e+00 | 0.1017 |
| 51639 | SF3B14 | cSCC_p1 | Human | Skin | cSCC | 1.20e-20 | -4.65e-01 | -0.1916 |
| 51639 | SF3B14 | cSCC_p10 | Human | Skin | cSCC | 1.20e-20 | -4.65e-01 | -0.2095 |
| 51639 | SF3B14 | cSCC_p11 | Human | Skin | cSCC | 1.20e-20 | -4.65e-01 | -0.2102 |
| 51639 | SF3B14 | cSCC_p3 | Human | Skin | cSCC | 1.20e-20 | -4.65e-01 | -0.2085 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030408 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
| hsa0304013 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
| hsa0304023 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
| hsa0304033 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
| hsa0304043 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
| hsa0304053 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
| hsa03040 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
| hsa030401 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
| hsa030402 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
| hsa030403 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
| hsa030409 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304014 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304024 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
| hsa0304034 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |